1771 related articles for article (PubMed ID: 27435464)
1. Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus.
Swanstrom JA; Plante JA; Plante KS; Young EF; McGowan E; Gallichotte EN; Widman DG; Heise MT; de Silva AM; Baric RS
mBio; 2016 Jul; 7(4):. PubMed ID: 27435464
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas.
Montoya M; Collins M; Dejnirattisai W; Katzelnick LC; Puerta-Guardo H; Jadi R; Schildhauer S; Supasa P; Vasanawathana S; Malasit P; Mongkolsapaya J; de Silva AD; Tissera H; Balmaseda A; Screaton G; de Silva AM; Harris E
J Infect Dis; 2018 Jul; 218(4):536-545. PubMed ID: 29618091
[TBL] [Abstract][Full Text] [Related]
3. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
[TBL] [Abstract][Full Text] [Related]
4. Cross-reactive dengue virus-derived monoclonal antibodies to Zika virus envelope protein: Panacea or Pandora's box?
Gunawardana SA; Shaw RH
BMC Infect Dis; 2018 Dec; 18(1):641. PubMed ID: 30526531
[TBL] [Abstract][Full Text] [Related]
5. Defining the impact of flavivirus envelope protein glycosylation site mutations on sensitivity to broadly neutralizing antibodies.
Contreras M; Stuart JB; Levoir LM; Belmont L; Goo L
mBio; 2024 Feb; 15(2):e0304823. PubMed ID: 38193697
[TBL] [Abstract][Full Text] [Related]
6. Human antibody response to Zika targets type-specific quaternary structure epitopes.
Collins MH; Tu HA; Gimblet-Ochieng C; Liou GA; Jadi RS; Metz SW; Thomas A; McElvany BD; Davidson E; Doranz BJ; Reyes Y; Bowman NM; Becker-Dreps S; Bucardo F; Lazear HM; Diehl SA; de Silva AM
JCI Insight; 2019 Apr; 4(8):. PubMed ID: 30996133
[TBL] [Abstract][Full Text] [Related]
7. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus.
Dejnirattisai W; Supasa P; Wongwiwat W; Rouvinski A; Barba-Spaeth G; Duangchinda T; Sakuntabhai A; Cao-Lormeau VM; Malasit P; Rey FA; Mongkolsapaya J; Screaton GR
Nat Immunol; 2016 Sep; 17(9):1102-8. PubMed ID: 27339099
[TBL] [Abstract][Full Text] [Related]
8. Cross-Reaction, Enhancement, and Neutralization Activity of Dengue Virus Antibodies against Zika Virus: A Study in the Mexican Population.
Montecillo-Aguado MR; Montes-Gómez AE; García-Cordero J; Corzo-Gómez J; Vivanco-Cid H; Mellado-Sánchez G; Muñoz-Medina JE; Gutiérrez-Castañeda B; Santos-Argumedo L; González-Bonilla C; Cedillo-Barrón L
J Immunol Res; 2019; 2019():7239347. PubMed ID: 31565661
[TBL] [Abstract][Full Text] [Related]
9. Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection.
Fernandez E; Dejnirattisai W; Cao B; Scheaffer SM; Supasa P; Wongwiwat W; Esakky P; Drury A; Mongkolsapaya J; Moley KH; Mysorekar IU; Screaton GR; Diamond MS
Nat Immunol; 2017 Nov; 18(11):1261-1269. PubMed ID: 28945244
[TBL] [Abstract][Full Text] [Related]
10. Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus Infection.
Premkumar L; Collins M; Graham S; Liou GA; Lopez CA; Jadi R; Balmaseda A; Brackbill JA; Dietze R; Camacho E; De Silva AD; Giuberti C; Dos Reis HL; Singh T; Heimsath H; Weiskopf D; Sette A; Osorio JE; Permar SR; Miley MJ; Lazear HM; Harris E; de Silva AM
J Clin Microbiol; 2018 Mar; 56(3):. PubMed ID: 29263206
[TBL] [Abstract][Full Text] [Related]
11. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor.
Dussupt V; Sankhala RS; Gromowski GD; Donofrio G; De La Barrera RA; Larocca RA; Zaky W; Mendez-Rivera L; Choe M; Davidson E; McCracken MK; Brien JD; Abbink P; Bai H; Bryan AL; Bias CH; Berry IM; Botero N; Cook T; Doria-Rose NA; Escuer AGI; Frimpong JA; Geretz A; Hernandez M; Hollidge BS; Jian N; Kabra K; Leggat DJ; Liu J; Pinto AK; Rutvisuttinunt W; Setliff I; Tran U; Townsley S; Doranz BJ; Rolland M; McDermott AB; Georgiev IS; Thomas R; Robb ML; Eckels KH; Barranco E; Koren M; Smith DR; Jarman RG; George SL; Stephenson KE; Barouch DH; Modjarrad K; Michael NL; Joyce MG; Krebs SJ
Nat Med; 2020 Feb; 26(2):228-235. PubMed ID: 32015557
[TBL] [Abstract][Full Text] [Related]
12. Identification of Anti-Premembrane Antibody as a Serocomplex-Specific Marker To Discriminate Zika, Dengue, and West Nile Virus Infections.
Hsieh SC; Tsai WY; Tsai JJ; Stone M; Simmons G; Busch MP; Lanteri M; Stramer SL; Balmaseda A; Harris E; Wang WK
J Virol; 2021 Sep; 95(19):e0061921. PubMed ID: 34232731
[TBL] [Abstract][Full Text] [Related]
13. Zika convalescent macaques display delayed induction of anamnestic cross-neutralizing antibody responses after dengue infection.
Valiant WG; Huang YS; Vanlandingham DL; Higgs S; Lewis MG; Mattapallil JJ
Emerg Microbes Infect; 2018 Jul; 7(1):130. PubMed ID: 30006514
[TBL] [Abstract][Full Text] [Related]
14. Rational Engineering and Characterization of an mAb that Neutralizes Zika Virus by Targeting a Mutationally Constrained Quaternary Epitope.
Tharakaraman K; Watanabe S; Chan KR; Huan J; Subramanian V; Chionh YH; Raguram A; Quinlan D; McBee M; Ong EZ; Gan ES; Tan HC; Tyagi A; Bhushan S; Lescar J; Vasudevan SG; Ooi EE; Sasisekharan R
Cell Host Microbe; 2018 May; 23(5):618-627.e6. PubMed ID: 29746833
[TBL] [Abstract][Full Text] [Related]
15. Humoral cross-reactivity between Zika and dengue viruses: implications for protection and pathology.
Priyamvada L; Hudson W; Ahmed R; Wrammert J
Emerg Microbes Infect; 2017 May; 6(5):e33. PubMed ID: 28487557
[TBL] [Abstract][Full Text] [Related]
16. Previous dengue or Zika virus exposure can drive to infection enhancement or neutralisation of other flaviviruses.
Oliveira RA; de Oliveira-Filho EF; Fernandes AI; Brito CA; Marques ET; Tenório MC; Gil LH
Mem Inst Oswaldo Cruz; 2019; 114():e190098. PubMed ID: 31411310
[TBL] [Abstract][Full Text] [Related]
17. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models.
Shukla R; Beesetti H; Brown JA; Ahuja R; Ramasamy V; Shanmugam RK; Poddar A; Batra G; Krammer F; Lim JK; Kale S; Lal AA; Swaminathan S; Khanna N
EBioMedicine; 2020 Oct; 60():102991. PubMed ID: 32949997
[TBL] [Abstract][Full Text] [Related]
18. Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development.
Elong Ngono A; Shresta S
Front Immunol; 2019; 10():1316. PubMed ID: 31244855
[TBL] [Abstract][Full Text] [Related]
19. Maternally Acquired Zika Antibodies Enhance Dengue Disease Severity in Mice.
Fowler AM; Tang WW; Young MP; Mamidi A; Viramontes KM; McCauley MD; Carlin AF; Schooley RT; Swanstrom J; Baric RS; Govero J; Diamond MS; Shresta S
Cell Host Microbe; 2018 Nov; 24(5):743-750.e5. PubMed ID: 30439343
[TBL] [Abstract][Full Text] [Related]
20. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection.
Stettler K; Beltramello M; Espinosa DA; Graham V; Cassotta A; Bianchi S; Vanzetta F; Minola A; Jaconi S; Mele F; Foglierini M; Pedotti M; Simonelli L; Dowall S; Atkinson B; Percivalle E; Simmons CP; Varani L; Blum J; Baldanti F; Cameroni E; Hewson R; Harris E; Lanzavecchia A; Sallusto F; Corti D
Science; 2016 Aug; 353(6301):823-6. PubMed ID: 27417494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
